Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revisionBoth sides next revision
home:diseases:celiac [07.12.2019] – [recent research] sallieqhome:diseases:celiac [07.13.2019] – [recent research] sallieq
Line 65: Line 65:
  
 Findings suggest that neither olmesartan nor other ARBs were associated with diarrhea among patients undergoing endoscopy. The spruelike enteropathy recently associated with olmesartan is likely a rare adverse effect and milder presentations are unlikely.  (({{pubmed>long:25023670}})) Findings suggest that neither olmesartan nor other ARBs were associated with diarrhea among patients undergoing endoscopy. The spruelike enteropathy recently associated with olmesartan is likely a rare adverse effect and milder presentations are unlikely.  (({{pubmed>long:25023670}}))
 +
 +In 2015 I read that 6 individuals in the USA are currently suing maker of Benicar. Somewhere I saw that 1.9 million individuals are currently taking Olmesartan Medoxomil.  6 in 1.9 million ? Seems pretty rare to me. (Editor)
  
 2018 data show that OLM is an Nrf2 activator, NFkB inhibitor and apoptosis inhibitor in an experimental model of ulcerative colitis. Overall, the study indicates that OLM shows promise as a potential therapy for the treatment of human inflammatory bowel diseases.  2018 data show that OLM is an Nrf2 activator, NFkB inhibitor and apoptosis inhibitor in an experimental model of ulcerative colitis. Overall, the study indicates that OLM shows promise as a potential therapy for the treatment of human inflammatory bowel diseases. 
home/diseases/celiac.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.